Cargando…

Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial

BACKGROUND/AIMS: Eradication of Helicobacter pylori infection with standard triple therapy (TT) has declined primarily because of increased antibiotic resistance. Sequential therapy (ST) has been suggested as an alternative to TT for the first-line treatment of H. pylori. The purpose of this study w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Joon Sung, Kim, Byung-Wook, Hong, Su Jin, Kim, Jin Il, Shim, Ki-Nam, Kim, Jie-Hyun, Baik, Gwang Ho, Kim, Sang Wook, Song, Hyun Joo, Kim, Ji Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933415/
https://www.ncbi.nlm.nih.gov/pubmed/27114421
http://dx.doi.org/10.5009/gnl15470
_version_ 1782441174587408384
author Kim, Joon Sung
Kim, Byung-Wook
Hong, Su Jin
Kim, Jin Il
Shim, Ki-Nam
Kim, Jie-Hyun
Baik, Gwang Ho
Kim, Sang Wook
Song, Hyun Joo
Kim, Ji Hyun
author_facet Kim, Joon Sung
Kim, Byung-Wook
Hong, Su Jin
Kim, Jin Il
Shim, Ki-Nam
Kim, Jie-Hyun
Baik, Gwang Ho
Kim, Sang Wook
Song, Hyun Joo
Kim, Ji Hyun
author_sort Kim, Joon Sung
collection PubMed
description BACKGROUND/AIMS: Eradication of Helicobacter pylori infection with standard triple therapy (TT) has declined primarily because of increased antibiotic resistance. Sequential therapy (ST) has been suggested as an alternative to TT for the first-line treatment of H. pylori. The purpose of this study was to compare the efficacy of ST with TT. METHODS: This was a multicenter, randomized open-label trial performed at nine centers in Korea. Patients with H. pylori infection were randomly assigned to receive either 7 day TT or 10 day ST. Eradication rates, drug compliance, and adverse events were compared among the two regimens. RESULTS: A total of 601 patients were enrolled between March 2011 and September 2014. The intention-to-treat eradication rates were 70.8% for TT and 82.4% for ST (p=0.001). The corresponding per protocol eradication rates were 76.9% and 88.8% for TT and ST, respectively (p=0.000). There were no statistically significant differences between the two regimens with respect to drug compliance and adverse events. CONCLUSIONS: ST achieved better eradication rates than TT as a first-line therapy for H. pylori eradication in Korea.
format Online
Article
Text
id pubmed-4933415
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Editorial Office of Gut and Liver
record_format MEDLINE/PubMed
spelling pubmed-49334152016-07-14 Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial Kim, Joon Sung Kim, Byung-Wook Hong, Su Jin Kim, Jin Il Shim, Ki-Nam Kim, Jie-Hyun Baik, Gwang Ho Kim, Sang Wook Song, Hyun Joo Kim, Ji Hyun Gut Liver Original Article BACKGROUND/AIMS: Eradication of Helicobacter pylori infection with standard triple therapy (TT) has declined primarily because of increased antibiotic resistance. Sequential therapy (ST) has been suggested as an alternative to TT for the first-line treatment of H. pylori. The purpose of this study was to compare the efficacy of ST with TT. METHODS: This was a multicenter, randomized open-label trial performed at nine centers in Korea. Patients with H. pylori infection were randomly assigned to receive either 7 day TT or 10 day ST. Eradication rates, drug compliance, and adverse events were compared among the two regimens. RESULTS: A total of 601 patients were enrolled between March 2011 and September 2014. The intention-to-treat eradication rates were 70.8% for TT and 82.4% for ST (p=0.001). The corresponding per protocol eradication rates were 76.9% and 88.8% for TT and ST, respectively (p=0.000). There were no statistically significant differences between the two regimens with respect to drug compliance and adverse events. CONCLUSIONS: ST achieved better eradication rates than TT as a first-line therapy for H. pylori eradication in Korea. Editorial Office of Gut and Liver 2016-07 2016-04-28 /pmc/articles/PMC4933415/ /pubmed/27114421 http://dx.doi.org/10.5009/gnl15470 Text en Copyright © 2016 by The Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, Korean College of Helicobacter and Upper Gastrointestinal Research, Korean Association the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, Korean Pancreatobiliary Association, and Korean Society of Gastrointestinal Cancer. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Joon Sung
Kim, Byung-Wook
Hong, Su Jin
Kim, Jin Il
Shim, Ki-Nam
Kim, Jie-Hyun
Baik, Gwang Ho
Kim, Sang Wook
Song, Hyun Joo
Kim, Ji Hyun
Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial
title Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial
title_full Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial
title_fullStr Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial
title_full_unstemmed Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial
title_short Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial
title_sort sequential therapy versus triple therapy for the first line treatment of helicobacter pylori in korea: a nationwide randomized trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933415/
https://www.ncbi.nlm.nih.gov/pubmed/27114421
http://dx.doi.org/10.5009/gnl15470
work_keys_str_mv AT kimjoonsung sequentialtherapyversustripletherapyforthefirstlinetreatmentofhelicobacterpyloriinkoreaanationwiderandomizedtrial
AT kimbyungwook sequentialtherapyversustripletherapyforthefirstlinetreatmentofhelicobacterpyloriinkoreaanationwiderandomizedtrial
AT hongsujin sequentialtherapyversustripletherapyforthefirstlinetreatmentofhelicobacterpyloriinkoreaanationwiderandomizedtrial
AT kimjinil sequentialtherapyversustripletherapyforthefirstlinetreatmentofhelicobacterpyloriinkoreaanationwiderandomizedtrial
AT shimkinam sequentialtherapyversustripletherapyforthefirstlinetreatmentofhelicobacterpyloriinkoreaanationwiderandomizedtrial
AT kimjiehyun sequentialtherapyversustripletherapyforthefirstlinetreatmentofhelicobacterpyloriinkoreaanationwiderandomizedtrial
AT baikgwangho sequentialtherapyversustripletherapyforthefirstlinetreatmentofhelicobacterpyloriinkoreaanationwiderandomizedtrial
AT kimsangwook sequentialtherapyversustripletherapyforthefirstlinetreatmentofhelicobacterpyloriinkoreaanationwiderandomizedtrial
AT songhyunjoo sequentialtherapyversustripletherapyforthefirstlinetreatmentofhelicobacterpyloriinkoreaanationwiderandomizedtrial
AT kimjihyun sequentialtherapyversustripletherapyforthefirstlinetreatmentofhelicobacterpyloriinkoreaanationwiderandomizedtrial